Evidence map›Paper›PMID 42746650›Full record

ReviewTzu chi medical journal

Targeting lipid metabolic vulnerabilities with small-molecule inhibitors in acute myeloid leukemia: Emerging insights and therapeutic opportunities.

Jui-Hung Yen, Trung Q Phan, Je-Wen Liou, Pei-Yi Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Tzu chi medical journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jui-Hung YenDepartment of Molecular Biology and Human Genetics, Tzu Chi University, Hualien, Taiwan.
Trung Q PhanInstitute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.
Je-Wen LiouDepartment of Biochemistry, School of Medicine, Tzu Chi University, Hualien, Taiwan.
Pei-Yi ChenDepartment of Molecular Biology and Human Genetics, Tzu Chi University, Hualien, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic reprogramming has recently been recognized as a hallmark of cancer. In acute myeloid leukemia (AML), clinically relevant metabolism-targeted therapies have primarily focused on inhibiting mitochondrial energy production; however, their clinical progress has been limited by substantial and nonspecific toxicity. Emerging evidence indicates that reprogramming of lipid metabolism represents a defining feature of leukemic transformation. Lipids not only serve as fundamental structural components of cellular membranes but also function as key signaling molecules and energy sources. In AML cells, lipid uptake, storage, and

Indexed as

Acute myeloid leukemiaFatty acid oxidationLipid metabolismMetabolic reprogrammingSmall-molecule inhibitors

Identifiers

PMID42746650
PMCPMC13577565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.